Ann: Phase 3 Common Cold Trial Results, page-10

Not sure.
They seem to be implying tht the Australian sites may well have been inverted by stripping out the Australian results which are almost identical but opposite..
In the 2019 trial, the GSS benefit of Nasodine in the viralinfected subjects (N=52) was 22.9% (p=0.048), but in the current trial, for Australian sites, the
benefit was reversed, with the water placebo outperforming Nasodine by 22.7% in the ITTi (N=181), the result being statistically significant (p=0.024).
They say there is no evidence they were switched.. 'at this time'.. does that mean that 'at another time' there might be eivdence? Who knows.